Mylan inks Vfend licensing deal with Pfizer; Japan's Mitsubishi aims for Chinese drug market;

> Mylan will have the right to start selling a U.S. generic version of Pfizer's Vfend antifungal drug in the first quarter of 2011 under a settlement and licensing agreement. Report

> Japanese trading house Mitsubishi and drug wholesaler Medipal Holdings aim to tap China's rapidly growing drug market by teaming up with Sinopharm Group, China's largest drug distributor. Report

> Australia's competition watchdog will not oppose the merger of global drug giants Schering-Plough and Merck, now that Merck has sold its Merial animal health business. Report

> Dainippon Sumitomo Pharma wrapped up its tender offer for shares of drugmaker Sepracor. Report

> A federal judge has ruled against Pfizer's request for sanctions against a witness in the Neurontin litigation whom it alleged had attempted to wrongly influence another witness in the case. Report

> The FDA warned Procter & Gamble that its Vicks DayQuil and NyQuil products with vitamin C have false and misleading labeling, and P&G said it would work with the agency to resolve its concerns. Report

Biotech News

> Is Amgen facing a significant delay on denosumab? Article

> OXiGENE plans to fork over $22 million worth of its shares to acquire VaxGen, gaining the developer's programs and $33 million in cash to fund its operations. Report

> Following hot on the heels of Phytopharm's announcement yesterday that its Parkinson's treatment had delivered promising results in animal and human studies, Oxford BioMedica thrilled analysts with a peek at some promising mid-stage data for its Parkinson's drug, ProSavin. News

> A panel of FDA experts had no trouble overcoming the concerns of regulators when they voted to approve Acorda Therapeutics' new drug to improve the ability of multiple sclerosis patients to walk. Report

> Harvard experts are championing a five-year window on generic protection. Article

Vaccine News

> With virtually round-the-clock swine flu news on cable these days, all sorts of news organizations are taking a crack at analyzing the business side of the pandemic equation. Report

> Dendreon stock jumped on the addition of 'heavyweight' board appointments. Report

> The post mortems on the Thai HIV vaccine trial continue to pour in following the revelation in the New York Times that AIDS researchers briefed on the results found out that a separate--and initially undisclosed--analysis of the trial data came up with a more modest efficacy rate. Article

> Vaccine manufacturers have a lot riding on the mass vaccination campaigns being rolled out around the globe. And not the least of their worries is the level of resistance health officials will face as they start inoculating people. Report

> Ann Arbor, MI-based NanoBio continues to rack up new, non-dilutive injections of cash to advance its vaccine adjuvant work. News

And Finally... People living near gardens, parks and other green spaces have lower rates of anxiety, depression and poor physical health. Report